{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-008972","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.464399+00:00","generated_at":"2026-06-25T21:56:05.945561+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Janux Q1 net loss $13.4M; cash $361.2M; IND filed for JANX007","bullets":["Net loss of $13.4M for Q1 2022 vs. $2.3M in Q1 2021; R&D spend $10.2M, G&A $4.9M.","Cash & investments $361.2M at March 31, 2022, down from $375.0M at Dec 31, 2021.","IND submitted for PSMA-TRACTr (JANX007); IND for EGFR-TRACTr (JANX008) expected 2H 2022.","Merck nominated a second target under the 2020 collaboration agreement in May 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-008972","json":"https://secwatch.observer/filing/0000950170-22-008972.json","markdown":"https://secwatch.observer/filing/0000950170-22-008972.md","text":"https://secwatch.observer/filing/0000950170-22-008972.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017022008972/0000950170-22-008972-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017022008972/janx-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:56:05.945561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}